HUTCHMED (Nasdaq/AIM:HCM;HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. 和黄医药(纳斯达克/伦敦证交所:HCM)是一家处于商业化阶段的创新型生物医药公司,致力于发现、全球开发和商业化治疗癌症和免疫性疾病的靶向药物和免疫疗法。和黃醫藥是一家處于商業化階段的創新型生物醫藥公司,致力于發現、全球開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法。